SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback.

Autor:	Bloom N; Center for Vaccine Innovation, La Jolla Institute for Immunology., Ramirez SI; Center for Vaccine Innovation, La Jolla Institute for Immunology.; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla., Cohn H; Department of Microbiology.; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, New York., Parikh UM; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania., Heaps A; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania., Sieg SF; Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve School of Medicine, Cleveland, Ohio., Greninger A; Department of Medicine, University of Washington, Seattle., Ritz J; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Moser C; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Eron JJ; Department of Medicine, University of North Carolina at Chapel Hill School of Medicine., Bajic G; Department of Microbiology., Currier JS; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles., Klekotka P; Eli Lilly and Company, San Diego., Wohl DA; Department of Medicine, University of North Carolina at Chapel Hill School of Medicine., Daar ES; Lundquist Institute at Harbor, University of California, Los Angeles Medical Center, Torrance., Li J; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Hughes MD; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Chew KW; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles., Smith DM; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla., Crotty S; Center for Vaccine Innovation, La Jolla Institute for Immunology.; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla., Coelho CH; Department of Microbiology.; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, New York.; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2024 Nov 15; Vol. 230 (5), pp. 1187-1196.
DOI:	10.1093/infdis/jiae371
Abstrakt:	Therapeutic monoclonal antibodies (mAbs) have been studied in humans, but the impact on immune memory of mAb treatment during an ongoing infection remains unclear. We evaluated the effect of infusion of the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD) mAb bamlanivimab on memory B cells (MBCs) in SARS-CoV-2-infected individuals. Bamlanivimab treatment skewed the repertoire of MBCs targeting spike toward non-RBD epitopes. Furthermore, the relative affinity of RBD MBCs was weaker in mAb-treated individuals compared to placebo-treated individuals over time. Subsequently, after mRNA coronavirus disease 2019 vaccination, MBC differences persisted and mapped to a specific reduction in recognition of the class II RBD site, the same RBD epitope recognized by bamlanivimab. These findings indicate a substantial role of antibody feedback in regulating MBC responses to infection, and single mAb administration can continue to impact MBC responses to additional antigen exposures months later. Competing Interests: Potential conflicts of interest. S. C. has consulted for GSK, JP Morgan, Citi, Morgan Stanley, Avalia NZ, Nutcracker Therapeutics, University of California, California State Universities, United Airlines, Adagio, Sanofi, and Roche. J. S. C. has consulted for Merck and Company. P. K. is an employee and shareholder of Eli Lilly and Company. K. W. C. has consulted for Pardes Biosciences. D. M. S. has consulted for and has equity stake in Linear Therapies, Model Medicines, and Vx Biosciences and has consulted for Bayer, Kiadis, Signant Health, and Brio Clinical. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu